Articles related to GLP-1s

As GLP‑1 medications become widely used for obesity and metabolic disease, clinicians are confronting a growing question: What should be done when patients don’t respond as expected?

“Semaglutide and, to a lesser extent, liraglutide were associated with significantly lower risk of worsening mental illness.” – Lead Study Researcher Heidi Taipale, PhD, University of Eastern Finland and Niuvanniemi Hospital

“In this observational study, women who used menopausal hormone therapy lost about 35% more weight than women taking tirzepatide alone. Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss,” says Maria Daniela Hurtado Andrade, M.D., Ph.D., endocrinologist at Mayo Clinic and senior author of the study.

Foundayo will be available via LillyDirect beginning April 6, with widespread availability through retail pharmacies and telehealth providers occurring soon after.

Reductions in lean body mass are likely concentrated in non-contractile components rather than reflecting a clear decline in muscle function.

“There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop.” – Senior study author Ziyad Al-Aly, MD; Washington University School of Medicine